| scholarly article | Q13442814 |
| P8978 | DBLP publication ID | journals/jcisd/ZarzyckaSNRGSST15 |
| P356 | DOI | 10.1021/CI500631E |
| P698 | PubMed publication ID | 25622654 |
| P5875 | ResearchGate publication ID | 271595884 |
| P50 | author | Christian Weber | Q37838769 |
| Jochen Grommes | Q42194818 | ||
| Sander B Nabuurs | Q125134909 | ||
| P2093 | author name string | Esther Lutgens | |
| Tilman M Hackeng | |||
| Oliver Soehnlein | |||
| Tom Seijkens | |||
| Gert Vriend | |||
| Claudia M van Tiel | |||
| Tina Ritschel | |||
| Barbara Zarzycka | |||
| Gerry A F Nicolaes | |||
| Roy Schrijver | |||
| Fabian Giehler | |||
| Arnd Kieser | |||
| P2860 | cites work | The Protein Data Bank: a computer-based archival file for macromolecular structures | Q27860989 |
| P433 | issue | 2 | |
| P304 | page(s) | 294-307 | |
| P577 | publication date | 2015-01-27 | |
| P1433 | published in | Journal of Chemical Information and Modeling | Q3007982 |
| P1476 | title | Discovery of small molecule CD40-TRAF6 inhibitors | |
| P478 | volume | 55 |
| Q38737500 | ATVB Distinguished Scientist Award: How Costimulatory and Coinhibitory Pathways Shape Atherosclerosis |
| Q26752784 | CD40 in coronary artery disease: a matter of macrophages? |
| Q30489011 | Docking Screens for Novel Ligands Conferring New Biology |
| Q63560435 | Efficacy and safety assessment of a TRAF6-targeted nanoimmunotherapy in atherosclerotic mice and non-human primates |
| Q58728912 | Emergence of Members of TRAF and DUB of Ubiquitin Proteasome System in the Regulation of Hypertrophic Cardiomyopathy |
| Q47224948 | Exploring immune checkpoints as potential therapeutic targets in atherosclerosis |
| Q40143741 | Genetic variants of TRAF6 modulate peritoneal immunity and the risk of spontaneous bacterial peritonitis in cirrhosis: A combined prospective-retrospective study |
| Q40506281 | Identification and characterization of antibacterial compound(s) of cockroaches (Periplaneta americana). |
| Q30849102 | Inhibition of CD40-TRAF6 interactions by the small molecule inhibitor 6877002 reduces neuroinflammation. |
| Q47599422 | Interleukin-1 Beta as a Target for Atherosclerosis Therapy: Biological Basis of CANTOS and Beyond |
| Q64258735 | Macrophage CD40 signaling drives experimental autoimmune encephalomyelitis |
| Q38935390 | Protein-protein interaction inhibitors: advances in anticancer drug design. |
| Q38396097 | Regulation of atherosclerotic plaque inflammation |
| Q63915433 | T cell co-stimulation and co-inhibition in cardiovascular disease: a double-edged sword |
| Q52661592 | TRAF molecules in inflammation and inflammatory diseases. |
| Q38733018 | TRAF6 Mediates Suppression of Osteoclastogenesis and Prevention of Ovariectomy-Induced Bone Loss by a Novel Prenylflavonoid. |
| Q49369729 | Targeting CD40-Induced TRAF6 Signaling in Macrophages Reduces Atherosclerosis. |
| Q89295152 | Targeting TRAF6 E3 ligase activity with a small-molecule inhibitor combats autoimmunity |
| Q90723624 | The CD40-CD40L Dyad as Immunotherapeutic Target in Cardiovascular Disease |
| Q47221242 | The CD40-CD40L Dyad in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis |
| Q88922346 | Toward Small-Molecule Inhibition of Protein-Protein Interactions: General Aspects and Recent Progress in Targeting Costimulatory and Coinhibitory (Immune Checkpoint) Interactions |
| Q49634849 | Tumor necrosis factor receptor-associated factor 6 as a nuclear factor kappa B-modulating therapeutic target in cardiovascular diseases: at the heart of it all. |
Search more.